GlobaLASEReach develops novel delivery systems to administer high-intensity 810nm and 980nm wavelength light energy onto and within biological systems for the treatment of pain. Later in 2023, our team will be bringing into the US marketplace a stand-alone laser light machine, that will allow larger areas to be treated while greatly reducing total treatment times and without reducing the energy density. In medicine, successful treatment response is of primary importance and reducing staff time to administer treatment is a cost savings to the healthcare provider and to each patient who receives treatments. 

We continue to develop our Rezalox Therapy System with its multiple photobiomodulation therapy hand pieces that each have their own unique capability to administer their high-intensity laser light energy. for the treatment of chronic musculoskeletal pain and which has the capacity to includes This Rezalox system’s patented air-fluid tight CO2 gas-cooled therapy hand piece will be entering clinical trials in 2024 for the treatment of chronic pelvic pain and pelvic floor myofasical pain, conditions that contribute to chronic bladder pain, interstitial cystitis, lower back pain, hip-piriformis muscle pain, and painful intercourse.  Chronic pelvic-bladder pain affects 35 million American women and over 16 million American men.

Biotechnology

Laser

GlobaLASEReach, LLC

Org chart

Similar companies